- Posted Date: August 18, 2015
- Open Date (Earliest Submission Date): October 20, 2015
- Letter of Intent Due Date(s): 30 days prior to the application due date
- Application Due Date(s): November 20, 2015; June 14, 2016; November 21, 2016; June 14, 2017; November 20, 2017; June 14, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- AIDS Application Due Date(s): Not Applicable
- Scientific Merit Review: March-April 2016, October-November 2016, March-April 2017, October-November 2017, March-April 2018, October-November 2018
- Advisory Council Review: May 2016, January 2017, May 2017, January 2018, May 2018, January 2019
- Earliest Start Date: July 2016, April 2017, July 2017, April 2018, July 2018, April 2019r
The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high-value informatics research resources to serve current and emerging needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on supporting activities necessary for improved user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justifications for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and/or deep engagement between the resource and the targeted research community should be described.